샘플 요청 목록

 카트 문의
시장보고서
상품코드
1941449

애완동물용 구충제 시장 규모, 점유율, 동향 분석 보고서 : 애완동물별, 투여 경로별, 제형별, 유형별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Pet Dewormers Market Size, Share & Trends Analysis Report By Pet, By Route Of Administration, By Dosage Form, By Type, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

애완동물용 구충제 시장 요약

세계의 애완동물용 구충제 시장 규모는 2025년에 26억 5,000만 달러로 추정되며, 2033년까지 53억 2,000만 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 9.2%의 성장률을 보일 것으로 예측됩니다. 반려동물 사육 수 증가, 인수공통전염병 및 소화기 기생충 위험에 대한 인식 증가, 예방 수의학의 보급 확대가 시장 성장을 촉진하고 있습니다.

반려동물의 건강에 대한 관심 증가, 반려동물의 인간화, 첨단 광범위 구충제 제품의 출시로 인해 시장 성장에 더욱 박차를 가하고 있습니다. 전 세계에서 기생충 매개 질환의 부담이 증가함에 따라 반려동물의 건강 유지를 위해 지속적인 기생충 예방이 필수적인 가운데, 반려동물용 기생충 구충제에 대한 수요가 증가하고 있습니다. 2024년 반려동물 기생충 협의회(CAPC) 데이터에 따르면 필라리아증 유병률은 미시시피주(개 15마리당 1마리)에서 가장 높았으며, 남부 주 전체에서 높은 수준을 보이고 있습니다. 한편, 텍사스, 루이지애나 등 고위험 지역에서는 검사한 고양이 200마리 중 1마리가 양성 반응을 보였습니다. 라임병을 포함한 진드기 매개 질환은 웨스트버지니아주에서개 6마리 중 1마리, 메인주와 버몬트주에서개 3마리 중 1마리, 아칸소주에서개 6마리 중 1마리가 앓고 있으며, 애너플라스마증은 아칸소주에서개 6마리 중 1마리가 앓고 있습니다. 벼룩에 대한 노출은 광범위하고 고양이 4마리 중 1마리,개 7마리 중 1마리가 벼룩에 노출되어 있으며, 일년 내내 예방관리가 필수적입니다. CAPC의 2025년 예측에 따르면 필라리아증의 주요 발생 지역은 남동부 지역으로 미시시피 강 유역과 대서양 연안을 따라 북상하는 경향을 보이고 있습니다. 이에 따라 기존에 저위험 지역으로 여겨졌던 지역에서도 수의사들은 정기적인 검사와 연중 구충 시술을 권장하고 있습니다. 이에 따라 필라리아, 장내 기생충, 외부 기생충을 동시에 예방하는 광범위 구충제에 대한 수요가 증가하고 있습니다. 엘랑코의 크레데리오 콰트로와 같은월1회 투여형 및 지속형 제제는 지속적인 예방 치료와 시장 성장을 지원하고 있습니다.

또한 구충 제품에 대한 규제 강화로 안전성, 약제 내성 대책, 수의사 주도의 기생충 관리가 강조되면서 반려동물용 기생충 구충제 시장이 재편되고 있습니다. 예를 들어 2024년 1월 유럽 일부 지역에서 시행된 규정은 처방약(POM-V)을 조제하기 전에 수의사의 신체검사를 의무화했습니다. 여기에는 대부분의 벼룩 및 구충제가 포함되며, 무분별한 반복 사용이 제한되는 한편, 전문적인 상담 수요가 증가하고 있습니다. 이러한 변화는 가이드라인을 준수하는 프리미엄, 광범위, 복합 구충제에 유리하게 작용하여 마리당 지출 증가와 처방전 중심의 안정적인 수요를 지원하고 있습니다. AAEP(미국수의임상영양학회), ESCCAP(유럽소동물임상영양학회) 등 전문기관과의 규제 정합성은 진단검사, 기록관리, 약제 내성 모니터링을 촉진하고, 치료 순응도 향상과 관련 수의의료 서비스 확대로 이어집니다. 그 결과, 시장은 가치와 컴플라이언스 중심의 성장 모델로 전환하고 있으며, 공중 보건 및 약물 내성 문제를 해결하면서 장기적인 안정성을 보장하고 있습니다.

자주 묻는 질문

  • 애완동물용 구충제 시장 규모는 어떻게 예측되나요?
  • 애완동물용 구충제 시장 성장을 촉진하는 요인은 무엇인가요?
  • 반려동물의 건강에 대한 관심이 애완동물용 구충제 시장에 미치는 영향은 무엇인가요?
  • 구충 제품에 대한 규제 강화가 애완동물용 구충제 시장에 미치는 영향은 무엇인가요?
  • 애완동물용 구충제의 주요 발생 지역은 어디인가요?
  • 애완동물용 구충제 시장의 경쟁 구도는 어떻게 되나요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 시장 변수의 동향과 범위

제4장 펫용 구충제 시장 : 애완동물별 추정·동향 분석

제5장 펫용 구충제 시장 : 투여 경로별 추정·동향 분석

제6장 펫용 구충제 시장 : 제형별 추정·동향 분석

제7장 펫용 구충제 시장 : 유형별 추정·동향 분석

제8장 펫용 구충제 시장 : 유통 채널별 추정·동향 분석

제9장 펫용 구충제 시장 : 지역별 추정·동향 분석

제10장 경쟁 구도

KSA

Pet Dewormers Market Summary

The global pet dewormers market size was estimated at USD 2.65 billion in 2025 and is projected to reach USD 5.32 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The market is experiencing growth driven by rising pet ownership, increasing awareness of zoonotic and gastrointestinal parasite risks, and growing adoption of preventive veterinary care.

Enhanced focus on pet health, humanization of pets, and availability of advanced, broad-spectrum deworming products further support market growth. The increasing global burden of parasite-borne diseases is driving demand for pet dewormers, as continuous parasite prevention becomes essential for pet health. According to 2024 Companion Animal Parasite Council (CAPC) data, heartworm prevalence is highest in Mississippi (1 in 15 dogs) and elevated across southern states, while 1 in 200 cats tested positive in high-risk areas such as Texas and Louisiana. Tick-borne diseases, including Lyme disease, affect 1 in 6 dogs in West Virginia, with anaplasmosis impacting 1 in 3 dogs in Maine and Vermont, and ehrlichiosis affecting 1 in 6 dogs in Arkansas. Flea exposure is widespread, affecting 1 in 4 cats and 1 in 7 dogs, making year-round preventive care crucial. The 2025 CAPC forecast highlights the Southeast as a heartworm epicenter, with northward spread along the Mississippi River and Atlantic coast, prompting veterinarians to recommend routine testing and year-round deworming even in traditionally low-risk regions. This has increased demand for broad-spectrum dewormers that combine heartworm, intestinal, and ectoparasite protection, with monthly or long-acting solutions such as Elanco's Credelio Quattro supporting consistent preventive care and market growth.

In addition, tighter regulations on antiparasitic products are reshaping the pet dewormers market by emphasizing safety, resistance management, and veterinarian-led parasite control. For instance, in January 2024 legislation in parts of Europe mandates a physical veterinary examination before dispensing Prescription-Only Medicines-Veterinarian (POM-V), including most flea and worming treatments, limiting unsupervised repeat use and increasing demand for professional consultations. This shift favors premium, broad-spectrum, and combination dewormers that comply with guidelines, supporting higher per-pet expenditure and stable prescription-driven demand. Regulatory alignment with professional bodies such as AAEP and ESCCAP promotes diagnostic testing, record-keeping, and resistance monitoring, enhancing adherence and expanding associated veterinary services. Consequently, the market is moving toward a value- and compliance-focused growth model, ensuring long-term stability while addressing public health and drug-resistance concerns.

Global Pet Dewormers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pet dewormers market report based on pet, route of administration, dosage form, type, distribution channel, and region.

  • Pet Outlook (Revenue, USD Million, 2021 - 2033)
  • Dogs
  • Cats
  • Horses
  • Other Pets
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
  • Topical
  • Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
  • Solid
  • Liquid
  • Others
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • Prescription
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Hospitals/Clinics
  • Retail/Pet Stores
  • E-commerce
  • Region Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Spain
    • Germany
    • Portugal
    • Romania
    • Slovakia
    • Czech Republic
    • Hungary
    • Poland
    • Italy
    • Ireland
    • UK
    • France
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Pet
    • 1.2.2. Route of administration
    • 1.2.3. Dosage form
    • 1.2.4. Type
    • 1.2.5. Distribution channel
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information/Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Model 1: Bottom-Up Analysis
    • 1.7.2. Model 2: Volume-Pricing Analysis
    • 1.7.3. Model 3: Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary/Related Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Awareness and education efforts regarding parasitic worms
      • 3.2.1.2. Growing importance of parasite control in pets
      • 3.2.1.3. Increasing expert scrutiny
      • 3.2.1.4. Increase in zoonotic diseases transfer from pets
      • 3.2.1.5. Evolving regulations
      • 3.2.1.6. Emergence of new parasitic worms
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Development of drug resistance
      • 3.2.2.2. Emergence of unverified treatments
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Pricing Analysis
  • 3.4. Market Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
    • 3.4.2. PESTEL by SWOT Analysis
  • 3.5. Estimated Animal Population, by Key Species & Key Countries, 2021-2024
  • 3.6. Product Pipeline Analysis

Chapter 4. Pet Dewormers Market: Pet Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pet Dewormers Market, By Pet Movement Analysis
  • 4.3. Pet Dewormers Market Estimates & Forecasts, by Pet, 2021 to 2033 (USD Million)
  • 4.4. Dogs
    • 4.4.1. Dogs Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 4.5. Cats
    • 4.5.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Horses
    • 4.6.1. Horses Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 4.7. Other Pets
    • 4.7.1. Other Pets Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pet Dewormers Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pet Dewormers Market, By Route of Administration Movement Analysis
  • 5.3. Pet Dewormers Market Estimates & Forecasts, by Route of Administration, 2021 to 2033 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Injectable
    • 5.5.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Topical
    • 5.6.1. Topical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pet Dewormers Market: By Dosage Form Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pet Dewormers Market, By Dosage Form Movement Analysis
  • 6.3. Pet Dewormers Market Estimates & Forecasts, By Dosage Form, 2021 to 2033 (USD Million)
    • 6.3.1. Solid
      • 6.3.1.1. Solid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Liquid
      • 6.3.2.1. Liquid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pet Dewormers Market: By Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Pet Dewormers Market, By Type Movement Analysis
  • 7.3. Pet Dewormers Market Estimates & Forecasts, by Type, 2021 to 2033 (USD Million)
    • 7.3.1. OTC
      • 7.3.1.1. OTC Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Prescription
      • 7.3.2.1. Prescription Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Pet Dewormers Market: By Distribution Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Pet Dewormers Market, By Distribution Channel Movement Analysis
  • 8.3. Pet Dewormers Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
    • 8.3.1. Veterinary Hospitals/Clinics
      • 8.3.1.1. Veterinary Hospitals/Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. Retail/Pet Stores
      • 8.3.2.1. Retail/Pet Stores Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. E-commerce
      • 8.3.3.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Pet Dewormers Market: By Regional Estimates & Trend Analysis

  • 9.1. Region Market Dashboard
  • 9.2. Region Market Share Analysis, 2025 & 2033
  • 9.3. North America
    • 9.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.2. U.S
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Competitive Scenario
      • 9.3.2.3. Regulatory Framework
      • 9.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Competitive Scenario
      • 9.3.3.3. Regulatory Framework
      • 9.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.4. Mexico
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Competitive Scenario
      • 9.3.4.3. Regulatory Framework
      • 9.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4. Europe
    • 9.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.2. UK
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Competitive Scenario
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3. Germany
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Competitive Scenario
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Competitive Scenario
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Competitive Scenario
      • 9.4.5.3. Regulatory Framework
      • 9.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Competitive Scenario
      • 9.4.6.3. Regulatory Framework
      • 9.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.7. Denmark
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Competitive Scenario
      • 9.4.7.3. Regulatory Framework
      • 9.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key Country Dynamics
      • 9.4.8.2. Competitive Scenario
      • 9.4.8.3. Regulatory Framework
      • 9.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.9. Norway
      • 9.4.9.1. Key Country Dynamics
      • 9.4.9.2. Competitive Scenario
      • 9.4.9.3. Regulatory Framework
      • 9.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.10. Portugal
      • 9.4.10.1. Key Country Dynamics
      • 9.4.10.2. Competitive Scenario
      • 9.4.10.3. Regulatory Framework
      • 9.4.10.4. Portugal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.11. Romania
      • 9.4.11.1. Key Country Dynamics
      • 9.4.11.2. Competitive Scenario
      • 9.4.11.3. Regulatory Framework
      • 9.4.11.4. Romania Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.12. Slovakia
      • 9.4.12.1. Key Country Dynamics
      • 9.4.12.2. Competitive Scenario
      • 9.4.12.3. Regulatory Framework
      • 9.4.12.4. Slovakia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.13. Czech Republic
      • 9.4.13.1. Key Country Dynamics
      • 9.4.13.2. Competitive Scenario
      • 9.4.13.3. Regulatory Framework
      • 9.4.13.4. Czech Republic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.14. Hungary
      • 9.4.14.1. Key Country Dynamics
      • 9.4.14.2. Competitive Scenario
      • 9.4.14.3. Regulatory Framework
      • 9.4.14.4. Hungary Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.15. Poland
      • 9.4.15.1. Key Country Dynamics
      • 9.4.15.2. Competitive Scenario
      • 9.4.15.3. Regulatory Framework
      • 9.4.15.4. Poland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.16. Ireland
      • 9.4.16.1. Key Country Dynamics
      • 9.4.16.2. Competitive Scenario
      • 9.4.16.3. Regulatory Framework
      • 9.4.16.4. Ireland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Competitive Scenario
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3. China
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Competitive Scenario
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Competitive Scenario
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5. Australia
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Competitive Scenario
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Competitive Scenario
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7. South Korea
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Competitive Scenario
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Competitive Scenario
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Competitive Scenario
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7. MEA
    • 9.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.2. South Africa
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Competitive Scenario
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.3. UAE
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Competitive Scenario
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.4. Saudi Arabia
      • 9.7.4.1. Key Country Dynamics
      • 9.7.4.2. Competitive Scenario
      • 9.7.4.3. Regulatory Framework
      • 9.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key Country Dynamics
      • 9.7.5.2. Competitive Scenario
      • 9.7.5.3. Regulatory Framework
      • 9.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
  • 10.3. Company Profiles
    • 10.3.1. Zoetis
      • 10.3.1.1. Participant's Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Product Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Boehringer Ingelheim
      • 10.3.2.1. Participant's Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Product Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Merck & Co., Inc.
      • 10.3.3.1. Participant's Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Product Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Elanco Animal Health
      • 10.3.4.1. Participant's Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Product Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Dechra Pharmaceuticals PLC
      • 10.3.5.1. Participant's Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Product Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Virbac
      • 10.3.6.1. Participant's Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Product Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Vetoquinol
      • 10.3.7.1. Participant's Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Product Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Hester Biosciences Limited
      • 10.3.8.1. Participant's Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Product Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Ceva Sante Animale
      • 10.3.9.1. Participant's Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Product Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Intas Pharmaceuticals Ltd.
      • 10.3.10.1. Participant's Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Product Benchmarking
      • 10.3.10.4. Strategic Initiatives
  • 10.4. List of other key players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제